Sia Daneshmand, MD, and Karine Tawagi, MD, join Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for non–muscle-invasive bladder cancer.
Nivolumab Combo Shows Efficacy, Safety in Muscle-Invasive Bladder Cancer
Phase 2 data support the potential of replacing cisplatin with nab-paclitaxel as a backbone therapy for those with muscle-invasive bladder cancer.
Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.
Lasting Responses Observed With TAR-200 in BCG-Unresponsive NMIBC
All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.
Emerging Immunotherapy Approaches For Urothelial Cancer
Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.
EU’s CHMP Recommends Nivolumab Combo Approval in Urothelial Carcinoma
Findings from the CheckMate-901 trial support the CHMP’s positive opinion of nivolumab plus chemotherapy in metastatic urothelial carcinoma.
FDA Approves Nogapendekin Alfa-inbakicept/BCG in BCG-unresponsive NMIBC
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.